A Comprehensive Nuclear Receptor Network for Breast Cancer Cells  by Kittler, Ralf et al.
Cell Reports
ResourceA Comprehensive Nuclear Receptor Network
for Breast Cancer Cells
Ralf Kittler,1,9,8 Jie Zhou,1,8 Sujun Hua,1,8,10 Lijia Ma,1 Yuwen Liu,1 Elisha Pendleton,1 Chao Cheng,2,3 Mark Gerstein,2,3,4
and Kevin P. White1,5,6,7,*
1Institute of Genomics and Systems Biology, Argonne National Laboratory and The University of Chicago, Chicago, IL 60637, USA
2Department of Molecular Biophysics and Biochemistry
3Program in Computational Biology and Bioinformatics
4Department of Computer Science
Yale University, New Haven, CT 06520, USA
5Department of Human Genetics
6Department of Ecology and Evolution
7Department of Medicine
The University of Chicago, Chicago, IL 60637, USA
8These authors contributed equally to this work
9Present address: Eugene McDermott Center of Human Growth and Development, The University of Texas Southwestern Medical Center,
Dallas, TX 75235, USA
10Present address: The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
*Correspondence: kpwhite@igsb.org
http://dx.doi.org/10.1016/j.celrep.2013.01.004SUMMARY
In breast cancer, nuclear receptors (NRs) play a
prominent role in governing gene expression, have
prognostic utility, and are therapeutic targets. We
built a regulatory map for 24 NRs, six chromatin state
markers, and 14 breast-cancer-associated transcrip-
tion factors (TFs) that are expressed in the breast
cancer cell line MCF-7. The resulting network reveals
a highly interconnected regulatory matrix where ex-
tensive crosstalk occurs among NRs and other
breast -cancer-associated TFs. We show that large
numbers of factors are coordinately bound to highly
occupied target regions throughout the genome, and
these regions are associated with active chromatin
state and hormone-responsive gene expression.
This network also provides a framework for strati-
fying and predicting patient outcomes, and we use
it to show that the peroxisome proliferator-activated
receptor delta binds to a set of genes also regulated
by the retinoic acid receptors and whose expression
is associated with poor prognosis in breast cancer.
INTRODUCTION
In cancer cells, deregulated gene expression changes the nor-
mal balance between tumor-suppressive and oncogenic gene
networks, altering the differentiation state of cells and enabling
them to proliferate, evade apoptosis, and metastasize. There-
fore, the inhibition of oncogenic transcription factors (TFs), or
the activation of tumor-suppressive TFs, in principle presents
a very effective therapeutic strategy for cancer treatment (Dar-
nell, 2002; Grivas et al., 2011). However, TFs are notoriously538 Cell Reports 3, 538–551, February 21, 2013 ª2013 The Authorspoor drug targets, with the notable exception of nuclear recep-
tors (NRs), which comprise a superfamily of 48 TFs in humans
(Evans, 2005) whose actions are typically dependent on small
lipophilic ligands for which agonists and antagonists are either
already available or could be developed (Chen, 2008; Grone-
meyer et al., 2004). This druggable potential, and the fact
that NRs regulate many cancer-relevant pathways, make them
important targets for cancer treatment. Additionally, misregu-
latedNR signaling plays amajor role in several common cancers,
for which breast cancer presents a prototypical example (Con-
zen, 2008).
In breast cancer, two NRs, estrogen receptor alpha (ERa) and
progesterone receptor (PR), have been shown to play a major
role in carcinogenesis and cancer progression. Both receptors
drive proliferation and promote survival in about 60%–70% of
breast cancer patients, and are therefore used to classify breast
cancers and to predict response to specific therapies (Harvey
et al., 1999). ERa is one of the main targets in breast cancer
therapy through drugs that directly inhibit ERa, such as tamox-
ifen, or through aromatase inhibitors that block the production
of its ligand estrogen. Although the study of NR function in breast
cancer has been limitedmainly to ERa and PR, recent studies re-
vealed the presence and potential importance of several addi-
tional NRs that may provide novel diagnostic markers and,
more importantly, novel targets for therapy (Hua et al., 2009; Ni
et al., 2011). However, the knowledge of the specific functions
of most NRs in breast cancer cells remains fragmentary.
Previous work mapping ERa binding sites genome-wide es-
tablished the target genes for this critical NR (Carroll et al.,
2006; Lin et al., 2007; Welboren et al., 2009). Subsequent
network analyses, including the binding site mapping of the
c-Myc protein, led to the discovery of novel biomarkers that
respond to the estrogen-induced transcriptional cascade (Hua
et al., 2008). Mapping of the ERa cofactor FoxA1 revealed that
ERa binding is dependent on this factor (Carroll et al., 2005;
Lupien et al., 2008), and mapping of retinoic acid receptor
(RAR) NRs uncovered a widespread antagonistic interaction of
liganded RARs with ERa in the regulation of breast cancer-asso-
ciated genes (Hua et al., 2009). This latter study highlighted the
potential of the integrated analysis of cis-regulatory regions for
multiple NRs. Here, we systematically map the genomic binding
sites of all NRs expressed in MCF-7 breast cancer cells. The
resulting map provides a framework to uncover the genetic
programs governed by NRs and to reveal their potential for
combinatorial action.
RESULTS
Mapping of the Genomic Binding Regions of NRs and
Cooperating TFs
We mapped the genomic binding sites of a total of 33 proteins
whose corresponding genes are expressed at moderate to
high levels in MCF-7 cells (Table S1). For completeness, we
included selected previously published MCF-7 binding site
data for ERa, GATA3, FOXA1, RARA, and RARG in our analysis
(Carroll et al., 2006; Hua et al., 2009). The total set of TFs studied
here includes 24 NRs, comprising half of the NRs encoded in the
human genome; seven JUN/FOS family members that dimerize
to form AP-1 TFs, and that can act as DNA-tethering factors
for NRs; CREB1, ATF-1, and ELK1, whose binding site motifs
are enriched in the genomic binding regions of ERa and RARs
in MCF-7 cells; as well as FOXA1, GATA3, XBP1-S, and SPDEF,
which are coexpressed with ERa in breast cancer. To assess
genomic and gene-expression states, we also mapped five
different chromatin-associated marks, RNA polymerase II, and
performed gene-expression profiling experiments under ligand
treatment.
A major obstacle to chromatin immunoprecipitation (ChIP)
studies involving large numbers of different TFs is the availability
of antibodies with high specificity and affinity required for immu-
noprecipitation of crosslinked chromatin-protein complexes.
To circumvent this problem, we developed a tag-based ChIP
approach using bacterial artificial chromosomes (BACs) trans-
genesis to express epitope (EGFP)-tagged TFs (Hua et al.,
2009; Poser et al., 2008). This approach offers several advan-
tages: the tagged TFs are expressed under the control of their
endogenous regulatory elements; the same antibody can be
used to assay different TFs, bypassing the need for TF-specific
antibodies and allowing direct comparison of binding affinities
among different TFs; and multiple BACs expressing different
TFs can be generated in series. These features make it possible
to perform ChIP analyses on the scale necessary to build com-
prehensive networks in mammalian cells for targeted sets of
functionally related TFs.
Using this approach, we generated MCF-7 cell lines that
stably express TFs tagged with EGFP either at their C termini
or N termini, and immunoprecipitations were performed with
an affinity-purified polyclonal antibody raised against EGFP.
Previous studies have shown that such tagged constructs are
expressed at levels comparable to endogenous proteins and
that the tagged proteins yield highly similar or identical binding
profiles as endogenous proteins mapped with specific anti-
bodies (Hua et al., 2009; Ne`gre et al., 2011; Poser et al., 2008).CApplying a p value cutoff of 1e-3, we identified between 705
and 20,770 binding regions per factor (Table S1). Previous
genome-wide mapping studies for NRs and cofactors such as
ERa, RARs, and FoxA1 in MCF-7 cells as well as GR, PPARg,
and AR in different cell types have revealed a prevalence of distal
binding relative to transcription start sites (TSSs) of protein-
coding genes (Carroll et al., 2006; Hua et al., 2008, 2009; John
et al., 2011; Lefterova et al., 2008; Lupien et al., 2008; Nielsen
et al., 2008; Reddy et al., 2009; Wang et al., 2009). When we
systematically analyzed the distance distribution of all NR/
cofactor binding sites relative to the TSS, we observed a wide
and continuous range of NR and other TF binding site distri-
butions. For many factors, there was indeed a relatively low
percentage (<50%) of binding regions proximal to TSSs (Figures
1A and 1B). However, NRs such as TR2L, TR2S, TR4, LXRa, and
THRa, as well as several NR-cooperating TFs, were frequently
bound to sites proximal to TSSs. Members of the NR superfamily
and cooperating TFs exhibit marked differences in their cis-regu-
latory binding characteristics relative to the TSS of their putative
target genes. Both proximal-biased and distal-biased NRs were
observed. These results indicate that the original observations of
distal-biased binding are not a general property of NRs but
instead a factor-specific property. Whenwe examined the evolu-
tionary conservation of regions bound by NRs and cooperating
TFs among vertebrates, we found that the binding regions for
all studied factors showed relatively high sequence conservation
as compared to genomic background, regardless of whether
a particular factor’s binding was proximal or distal biased. This
pervasive evolutionary conservation of the NR binding regions
supports their putative roles as functional cis-regulatory ele-
ments (Figure 1C).
Transcription Factor Motifs in NR/Cofactor Binding
Sites
We searched the binding regions of each factor for enrichment
of known TF motifs (Table S2). This analysis identified in most
cases (i.e., when the specific motif was known) the canonical
motif of a given factor. We identified putative binding motifs
from several TF families that may affect the binding or coregulate
transcriptional effects of these factors. Transcription factors
such as FoxA1 have been proposed to act as pioneering TFs
that facilitate the binding of multiple NRs such as ERa and
RARs to enhancers. Interestingly, we found that the enrichment
of Forkhead motifs appears to occur only in subset of NRs (ERa,
RARA, RARG, COUP-TFII, REV-ERBA, PPARD, PPARG, RORC,
RXRB, TR4, and VDR), which suggests that Forkhead factors
such as FoxA1 may not be general NR pioneer factors in a given
cell lineage and additional TFs may be required to facilitate the
actions of other NRs.
Binding of Multiple NR/Cofactors Defines Active
Chromatin Regions
In total, we identified 200,140 binding regions for all 39 factors, of
which only 32% are unique (i.e., they do not overlap with other
binding regions). Thus, there appears to be a marked binding
redundancy for NRs and their putative cooperating TFs. Previous
studies have revealed the existence of highly occupied target
binding regions in the genome (HOT regions) (Dunham et al.,ell Reports 3, 538–551, February 21, 2013 ª2013 The Authors 539
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Figure 1. Distribution and Evolutionary Conservation of NR and Associated TF Binding Sites in MCF-7 Cells
(A) Frequencies of binding sites for each factor residing within 2 and 10 kb upstream or downstream to annotated TSSs.
(B) Distribution of binding sites for each factor relative to TSSs. Denser color indicates higher frequency of binding.
(C) Conservation profile for the binding sites of each factor. PhastCons conservation scores (Siepel et al., 2005) within ±3 kb of the center of the binding sites were
averaged for all binding sites of each given factor. The control was generated using ±3 kb flanking sequence of 3,000 randomly chosen binding sites.
See also Tables S1 and S2.2012; Gerstein et al., 2010, 2012; Moorman et al., 2006; Ne`gre
et al., 2011; Roy et al., 2010) When we systematically analyzed
the binding complexity of shared genomic regions (Figure 2A;
Table S3), we found that regions with a binding complexity of
more than 8 occurred more frequently than randomly expected
(Figure 2B). We did not find significant differences in the
evolutionary conservation between binding regions of low and
high complexity (Figure S1A), but complexity appeared to be
inversely correlated to the binding regions’ mean distance to
TSSs (Figure S1B). Highly complex regions were significantly en-
riched near genes that play a role in cancer development and
progression, including breast cancer biology (Table S4; Fig-
ure S1C). For example, we observed the binding of multiple540 Cell Reports 3, 538–551, February 21, 2013 ª2013 The Authorsfactors nearby breast cancer-driving genes such as MYC and
CCND1 (Figure 2A); these regions were also bound by multiple
TFs in the ER-expressing breast cancer cell line T-47D and in
multiple other cell lines (Figures S2A and S2B) as identified in
the ENCODE data (Dunham et al., 2012). The functional signifi-
cance of such HOT regions is unknown, although in Drosophila
they have been shown to be associated with accessible or
open chromatin (Ne`gre et al., 2011; Roy et al., 2010). We
wondered whether this property was conserved in the human
genome and whether HOT regions may play a role in the tran-
scriptional regulatory network governed by NRs in breast
cancer. We therefore performed genome-wide analyses of
chromatin and transcriptional activity in MCF-7 cells. We used
CA B
Figure 2. Binding of Multiple TFs to Shared Binding Regions
(A) The distribution of TF binding density complexity for all binding sites, and annotations for each complexity group. Complexity was calculated using the
Gaussian kernel density estimation methods (Ne`gre et al., 2011).
(B) The distribution of observed and randomly expected binding complexity. The randomly expected complexity was obtained frompermutating the binding sites.
(C) HOT regions associated with the known breast cancer-driving genes MYC and CCND1. The position of the binding regions in their genomic context are
depicted as black bars. The gene sequences are depicted in blue (thick bars represent coding exons, thin bars represent untranslated exons, and blue lines
represent introns). Ochre bars depict HOT regions. Base positions on the respective chromosomes and scale bars are shown at the bottom of the panel. See also
Figure S2.
See also Tables S3, S4, and Figure S1.genome-wide formaldehyde-assisted isolation of regulatory
elements (FAIRE) to determine the chromatin accessibility of
binding regions. We found a strong correlation between the TF
binding complexity and mean FAIRE scores (Figure 3A). Addi-
tional analyses revealed that HOT regions have relatively high
mean levels of histone modifications that are specific for active
chromatin such as H3K4-trimethylation (H3K4me3, marker forCactive promoter regions) (Figure 3B), H3K4-monomethylation
(H3K4me1, marker for active promoter-distal elements or
enhancers) (Figure 3C), H2AZ-acetylation (H2AZace, marker
for active elements) (Figure 3D), and H3R17 asymmetric dime-
thylation (H3R17me2, marker for the activity of the NR coac-
tivator CARM1) (Figure 3E), whereas H3K27-trimethylation
(H3K27me3, marker for transcriptionally inactive chromatin) isell Reports 3, 538–551, February 21, 2013 ª2013 The Authors 541
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Figure 3. Correlation of Chromatin and Transcriptional Activity Parameters with TF Binding Complexity
(A–F) Chromatin activity and TF complexity in MCF-7 cells. Median ChIP or FAIRE signal intensities in MCF-7 cells were plotted against complexity scores
for FAIRE (A), H3K4me3 (B), H3K4me1 (C), H2AZace (D), H3R17me2 (E), and H3K27me3 occupancies (F). Signal intensities were calculated from three
replicates.
(G–I) Estrogen-regulated transcriptional activity and TF complexity in MCF-7 cells. Median ChIP signal intensities were plotted against complexity scores for
polymerase II occupancy (G). Signal intensities were calculated from three replicates. Steady-state expression changes caused by estrogen treatment for 24 hr
obtained frommicroarray analyses as the absolute values of log2-fold changes of genes whose TSSs arewithin 50 kb to a HOT region with an ERa binding site (H).
Immediate gene-expression changes caused by estrogen in MCF-7 cells were calculated as the median number of reads in the binding region after pooling the
two replicates and normalized with the total number of reads from previously published GRO-seq data (Hah et al., 2011) (I).
See also Figure S3.
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Figure 4. Nuclear Receptor Regulatory Network in Breast Cancer
(A) Regulatory network of NRs and associated TFs in MCF-7 cells. The network was inferred for three classes of edges representing the following types of
functional interaction between NRs: type I (binding of one TF within 50 kb range of the promotor of the other TF, depicted in gray); type II (expression level of one
factor affects expression of the target gene of another factor, depicted in red); type III (activation of one NR affects the expression of another factor, depicted in
green). The colors of the nodes indicate three classes of TFs: NR with known ligands (depicted in blue); Orphan NR (depicted in red). TFs associated with NRs
(depicted in yellow). The network is organized using unweighted spring embedded method with Cytoscape.
(B) Significantly enriched network motifs. Type II and III edges are depicted in red. The frequencies of the most common factors for each node of each enriched
motif are displayed in the histograms (see also Figures S3C–S3H).
See also Tables S5, S6, S7, and Figure S4.not correlated with hotness (Figure 3F). We also found RNA poly-
merase II (Figure 3G), which binds to both promoter-proximal
and promoter-distal elements, to be markedly enriched at HOT
regions. To determine if these chromatin associations were
directly relevant to transcriptional state, we analyzed changes
in transcript expression upon estrogen treatment. We found
that TF binding complexity is strongly correlated with both
steady-state levels of estrogen-regulated transcripts from HOT
regions in MCF-7 cells (Figure 3H) and with levels of nascent
estrogen-regulated RNAs associated with transcriptionally en-
gaged RNA polymerases (Figure 3I) including enhancer RNAs
(eRNAs) (Figure S3A) as inferred from GRO-seq analyses of
estrogen-regulated transcripts in MCF-7 cells (Hah et al.,
2011). Further, we found an association of HOT regions with
‘‘anchor genes‘‘ (i.e., genes associated with multiple ER binding
regions interacting by looping) (Figure S3B) as well as a positive
correlation of HOT regions with looping anchor sites (Figure S3C)
when we analyzed the ER-bound human chromatin interactome
(Fullwood et al., 2009). Finally, when we analyzed copy number
variation in breast cancer using the Cancer Genome Atlas
(CGA) data set of 886 breast tumor samples (Cancer Genome
Atlas Network, 2012), we found that the complexity of NR HOT
regions is positively correlated with genomic amplification (Fig-
ure S3D) and negatively associated with deletions (Figure S3E).
These findings collectively indicate that genomic regions bindingCmultiple NRs and associated TFs represent highly active chro-
matin sites, which may be key regions for transcriptional regula-
tion in breast cancer cells.
Analysis of NR Regulatory Networks
We next examined the network of regulatory relationships
between NRs and their associated TFs. We constructed a
network where nodes represent the mapped factors and edges
represent three different types of regulatory relationships: type
I, putative physical interaction of two factors, inferred from
binding between a TF and the genomic region of another TF-en-
coding gene; type II, putative functional interaction inferred from
an effect of the expression level of a factor on the expression of
the target genes of a NR; and type III, putative functional interac-
tion inferred froma change in the expression level of a factor after
treatment with the ligand of a NR (see Extended Experimental
Proceduresfor details). We constructed a network (Figure 4A)
that shows high connectivity with an average of 11 edges per
node. This network reveals a potential for rapid spread of regu-
latory information, requiring no more than four connections to
connect any pair of TFs in the network. When we separated
the TFs in the regulatory network into ‘‘central’’ and ‘‘peripheral’’
TFs based on their centrality in the network (Figure S4A), we
found that the putative target genes of central TFs have a
much higher enrichment of gene sets that are associated withell Reports 3, 538–551, February 21, 2013 ª2013 The Authors 543
breast cancer than the target genes of peripheral TFs (p = 0.008)
(Table S5; Figure S4B). This finding establishes a key role of
central TFs in breast cancer-associated gene regulation. These
factors include ERa, RARs, GR, GATA3, and FoxA1 that are
known to play key roles in breast cancer biology, but also several
NRs whose roles in breast cancer biology have not been heavily
studied in this context, including PPARd, VDR, and THRa. Our
findings suggest that these factors might have important func-
tions in NR-mediated gene regulation in breast cancer. We
explore one of these factors, PPARd, further below.
We next searched for significantly overrepresented network
motifs that are likely to represent building blocks of TF regulation
(Figure 4B; Figures S4C–S4H). We found six significantly en-
riched network motifs in the regulatory network. The three
most common motifs (1, 2, and 4) correspond to coregulation
or feed-forward loops where a TF is regulated by two other
TFs. Among the coregulated TFs we found most frequently for
these motifs were the paralogs FOS and FOSB, which have
key functions as components of AP-1 in both normal and malig-
nant mammary epithelial cells (Eferl and Wagner, 2003; Mus-
grove and Sutherland, 2009), as well as the RAR-related orphan
receptor gamma. In two other motifs (3 and 6), we found ERa and
RARs most frequently as reciprocally regulated TFs, indicating
that this type of regulation is common for these antagonistic
regulators of breast cancer cell growth. This network analysis
indicates distinct regulatory patterns for different NRs and asso-
ciated TFs. We therefore sought to determine whether these
regulatory interactions might also be reflected in the regulation
of common target genes. To quantify coincident binding of
TFs, we computed pairwise binding similarities for all factors
(Tables S6 and S7). To systematically group factors sharing
common binding regions in an unsupervised manner, we em-
ployedmultidimensional scaling (MDS) (Figure 5A). We identified
three major groups whose members may function in a coordi-
nated manner. The first group (ERa-RAR related) contained
ERa, RARa, RARg, GR, PPARd, PPARg, VDR, RORa, RXRb,
and the two factors FoxA1 and GATA3 that are coexpressed
with ERa and define the luminal A breast cancer subtype (Ber-
nardo et al., 2010; Eeckhoute et al., 2007; Kong et al., 2011;
Kouros-Mehr et al., 2006; Wilson and Gigue`re, 2008). Because
ERa, RARs, GATA3, and FOXA1 have been previously identified
as functionally interacting TFs in the regulation of breast cancer
cell growth, we propose that the factors in this group cluster play
a key role in the transcriptional regulation of cell growth in breast
cancer. Common target genes of this group showed significant
enrichment for cell-cycle and proliferation-related gene ontol-
ogies (Table S8). A total of 13.7% of the genes that are regulated
by these NRs are among the BC1000 list of important breast
cancer genes (Witt et al., 2006). The second group (TSS proximal
TFs) contains NRs (TR2L/S, THRa, NURR1, RXRa COUP-TFI,
and LXRa) and associated TFs (ATF1, CREB1, SPDEF, XBP-
1S, and JUNB) that bind near TSSs of their putative targets,
leading to the hypothesis that genes adjacent to these pro-
moter-proximal elements are globally coregulated by these
TFs. This hypothesis is supported by the increased levels of
the histone mark H3K4me3 that is specific for actively tran-
scribed promoters in shared binding regions for these fac-
tors proximal to TSSs of genes (Figure 5B). Interestingly, we544 Cell Reports 3, 538–551, February 21, 2013 ª2013 The Authorsobserved similarly high levels of H3K4me3 in TSS-distal binding
regions for factors of this group, which may be due to previously
unannotated promoters or may indicate that H3K4me3 marks
can be associated with distal-enhancer elements bound by
these factors. The third group (Jun-Fos family) contains six out
of seven Jun/Fos family members, as well as ELK1, PR, PPARa,
AR, and NR4A1, suggesting a functional interaction between
AP-1 and these NRs. Interestingly, we found that the presence
of AP-1 family members at binding regions of NRs in this group
corresponds to a reduction in the levels of several markers for
chromatin activity (Figure 5C). This observation contrasts with
AP-1 associations with group 1 and group 2 factors, whose col-
lective binding is associated with increased chromatin activity.
Thus, the three groups appear to be not only distinct by virtue
of binding site clustering, but also to differ based on functionally
relevant chromatin features that mark enhancers, promoters,
and chromatin activity states.
We note that there is congruency between these groups and
the regulatory network; e.g., we found 9 out 11 of the factors
of the ERa-RAR related group and 8 out of 11 of the Jun-Fos
family group as central TFs or peripheral TFs in the network,
respectively. Overall, both the inference of the regulatory net-
work and the global analysis of the factors’ binding similarities
provide a resource to develop hypotheses for functional interac-
tions between different NRs and accessory TFs.
NRs as Key Regulators of Oncogenic Programs in Breast
Cancer
We further investigated the functional relevance of HOT regions
by asking whether breast cancer-relevant genes are enriched for
HOT regions. Indeed, there is a marked and statistically signifi-
cant enrichment for breast cancer-relevant genes associated
with HOT regions (Figure S1C) and an association between
binding complexity and copy number variation in breast cancer
(Figures 2D and 2E). These findings indicate that these cis-regu-
latory regions may play a critical role in the regulation of the ex-
pression of genes driving breast cancer. Because HOT regions
containing multiple NRs are associated with genes important
for breast cancer development or progression, combinatorial
targeting of interacting NRs that regulate these genes may pro-
vide new therapeutic options for breast cancer treatment.
To identify NRs as therapeutic targets, we integrated binding
site, expression, and clinical outcome data. We first correlated
NR messenger RNA levels from published gene-expression
profiling studies with patient survival data to identify NRs/asso-
ciated TFs implicated in breast cancer progression. This analysis
verified known genes such as ERa, FOXA1, and GATA3 as
predictors for good prognosis (Figure S5A). Interestingly, we
also identified PPARd expression as a strong predictor for poor
clinical outcome in this analysis (p = 2.27e-5) (Figure 6A); i.e.,
patients with breast tumors expressing high levels of PPARd
had a markedly lower survival rate. This negative association
between PPARd expression and clinical outcome held up
(p = 0.027) when we analyzed tumor samples expressing high
levels of ERa (Figure 6B), indicating that PPARd expression is
a prognostic marker that is independent of ERa status. Treat-
ment of MCF-7 cells with the highly selective PPARd agonist
GW0742 increased cell proliferation by 60% (p = 3.18e-5)
AB C
Figure 5. Grouping of NRs and Associated TFs Based on Their Binding Similarity
(A) MDS of TF target similarities. TheMDS plot was generated from pair-wise binding distances. The groups in theMDS plot were arbitrarily selected based on TF
function and relative proximities in the MDS plot.
(B) H3K4me3 signal around three MDS group TFs binding regions. To calculate ChIP signal, we picked up representative regions for each MDS group. Each
representative region fits criteria: (1) no less than five TFs binding in that region; (2) more than 50% of TFs are in a certain MDS group (ER-RAR related, TSS
proximal TFs, or Jun-Fos family). According to their distance to all annotated TSS, each representative region was further divided into two subgroups: proximal to
TSS (%10 kb, red box in figure) and distal to TSS (>10 kb, blue box). From the figure, the ChIP signals are higher in ‘‘TSS Proximal TFs’’ group regions, lower in
‘‘Jun-Fos Family’’ regions andwith ‘‘ER-RARRelated’’ in themedian. Also, it seems the ChIP signals only related to the TFs binding in the same regions rather than
the distance from the binding region to annotated TSS.
(C) Jun and Fos family member cobinding effect on chromatin ChIP signals. Regression analysis was performed to detect the cobinding effect on chromatin
marks between Jun-Fos family related NR binding sites and other TF binding sites, and the coefficient and confidence intervals were plotted (see Extended
Experimental Procedures for details). Five out of six chromatin activity marks displayed significant differences between the two groups, suggesting functional
interaction between these five NRs and Jun-Fos family members (AP1).
See also Table S8.(Figure 6C), demonstrating a role of PPARd as a driver of breast
cancer growth in ER-positive breast cancer cells. Further, we
tested the effects of two PPARd antagonists (GSK0660 andCGSK3787) on MCF-7 cell growth alone and in combination with
the RAR ligand all-trans retinoic acid (ATRA). We found an addi-
tive growth-suppressive effect of PPARd antagonists and theell Reports 3, 538–551, February 21, 2013 ª2013 The Authors 545
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Figure 6. Antagonistic Actions of PPARd and RARs in Breast Cancer
(A and B) PPARd expression as prognostic indicator. Kaplan-Meier curves of overall survival among all 295 (A) (Chang et al., 2005) patients and 226 patients with
ERa-positive tumors (B) classified by PPARD expression. The patient samples are grouped in three categories based on PPARd expression (A: low [n = 92],
medium [n = 91], and high [n = 112]; B: low [n = 85], medium [n = 75], and high [n = 112]). All p values were obtained from log-rank tests.
(legend continued on next page)
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RAR agonist (Figures S5B and S5C), which supports our model
of an antagonistic relationship of PPARd and RAR in breast
cancer.
Previous studies suggested a growth-promoting role for
PPARd in ER-positive cell lines (Stephen et al., 2004) and in the
MMTV/neu mouse model that resembles human Her2+/ER
breast cancer (Schug et al., 2007; Schug et al., 2008). Also,
PPARd may be activated by retinoic acid to induce the expres-
sion of prosurvival genes in breast cancer (Schug et al., 2007).
Retinoic acid typically mediates inhibition of cell growth through
activating its canonical receptors, the RARs. The partitioning of
retinoic acid between the two receptors was suggested to be
regulated by the levels of two intracellular lipid-binding proteins,
CRABP-II and FABP5 (Schug et al., 2007). Thus, opposing
effects of retinoic acid on cell growth may result from alternate
actions on two different NRs. Interestingly, we identified PPARd
and RARs as highly overlapping in their target genes and binding
profiles (Figure 6D; Table S9). A total of 27.3% of PPARd binding
sites overlap with RAR binding sites, a number that is highly
statistically significant (Z score 28.5, p < 1e-16). Also, both
NRs belong to the central group of TFs in the regulatory network
that we constructed (Figure 4A), and PPARd is the most
commonly factor found as the starting point in network motif V,
which corresponds to a regulatory chain. These results suggest
that PPARd and RARs may regulate a common subset of genes
and may be interregulated in breast cancer. When we analyzed
the expression of putative direct RAR and PPARd targets that
were derived from our cell-line experiments in breast tumor cells
from patient samples, we observed that a cluster with low ex-
pression in Luminal A and B types but high expression in the
aggressive HER2+/ER subtypes contains a high proportion of
RAR targets as well as PPARd targets (Figure 6E). We also found
two gene clusters, with low expression in the HER2/ER
subtype but high expression in Luminal A and B and Normal-
like types, which contain a large fraction of genes that are
putative direct targets of RARs and PPARd. Because of the
opposite effects PPARd and RARs have on breast cancer cell
growth, we predicted that the two NRs may antagonistically
regulate the expression of common target genes. When we
tested the effects of the PPARd agonist GW0742 and the RAR
agonist ATRA on gene expression by microarray analysis, we
observed opposite effects on the expression levels of common
putative target genes (Figures S5D and S5E).
Our observation that many PPARd targets are breast cancer-
relevant genes and are specifically expressed in different breast
cancer subtypes suggested that these genes might possess
significant prognostic value. We therefore analyzed the clinical(C) PPARd activation increases cell proliferation. MCF-7 cells were treated with
measured with a BrdU assay. Error bars represent SD (n = 5).
(D) Venn diagram displaying shared putative target genes of PPARd, RARg, and R
the TSSs.
(E) Hierarchical clustering of 146 breast tumor set using the UNC Intrinsic gene s
targets were plotted. The density was calculated as the proportion of TF putativ
(F and G) PPARd targets as prognostic indicators. Kaplan-Meier curves of overa
ERa-positive tumors (G) classified by PPARd target score. The patient samples a
medium [n = 82], and high [n = 146]; G: low [n = 66], medium [n = 68], and high [
See also Figure S5 and Table S9.
Coutcome for each tumor sample dependent on the expression
of putative direct targets of PPARd. For this analysis, we defined
for each tumor sample an PPARd target score, which measures
the correlation between PPARd target gene expression profiles
in MCF-7 cells and the gene-expression profile in a given tumor
sample. We examined the correlation between PPARd signature
scores and clinical outcomes for a cohort of expression profiles
from 295 breast tumor patients (van de Vijver et al., 2002). We
previously showed for this cohort that elevated RAR target
scores were associated with positive clinical outcomes in this
data set, indicating that activation of RAR targets is associated
with patient survival (Hua et al., 2009). Using PPARd target
scores, Kaplan-Meier survival analysis demonstrated a highly
significant correlation between PPARd target scores and overall
patient survival for the entire cohort (p = 3.76e-4) (Figure 6F) as
well as patients with ER-positive tumors only (p = 0.005) (Fig-
ure 6G). High and moderate PPARd target scores indicated
poor prognosis while low scores strongly indicated positive clin-
ical outcomes. Taken together, these findings substantiate an
antagonistic functional interaction of PPARd and RARs and
suggest that the combinatorial treatment with PPARd antago-
nists and selective RAR agonists may be an effective strategy
for breast cancer therapy for certain subsets of patients.
DISCUSSION
Nuclear receptors are essential to normal development, homeo-
stasis, and disease processes. The complete regulatory net-
works that they modulate have never before been delineated in
any single system. In the case of breast cancer, NRs are well
known to play critical roles but only a handful of factors have
been examined in depth. The MCF-7 cell line has been a particu-
larly useful model to identify the global genomic targets of a
handful of NRs (Carroll et al., 2005, 2006; Hua et al., 2008,
2009; Kong et al., 2011; Lin et al., 2007; Lupien et al., 2008; Wel-
boren et al., 2009), and thus served here as a natural launch point
to build the first comprehensive NR network in human cells.
Our results for the full set of NRs and several associated
sequence-specific TFs revealed several key characteristics of
NR action. Importantly, the recruitment of multiple factors to
the same regions, described previously for a smaller set of
TFs, appears to be a common theme in transcriptional regulation
among these factors. The marked correlation of the complexity
of HOT regions with several markers for chromatin and tran-
scriptional activity indicates functionally relevant cis-regulatory
elements. These reflect active enhancers or promoters in this
breast cancer cell-line genome. Currently, a major challenge100 nM of the PPARd agonist GW0742 or vehicle for 24 hr. Proliferation was
ARa as defined by the presence of at least one binding region within 50 kb to
et (Hu et al., 2006). The density profiles for PPARd, RARa, and RARg putative
e targets in 50 neighbors for each gene in the cluster.
ll survival among all 295 (F) (Chang et al., 2005) patients and 226 patients with
re grouped in three categories based on PPARd target score (F: low [n = 67],
n = 92]). All p values were obtained from log-rank tests.
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for the interpretation of TF binding site data is the discrepancy
between the very large number of binding regions and the
markedly lower number of significant direct effects of a given
TF (typically on the order of onemagnitude) on transcript expres-
sion. The complexity of HOT regions may serve as an important
indicator for functionally relevant binding regions of NRs in
breast cancer. Thus, the binding site map of NRs presented
here helps to pinpoint the identification of a set of several
hundred HOT regions (3,706 with complexity > 8) from a set of
tens of thousands of unique binding regions. These may reflect
regulatory regions that have the largest effects on gene regula-
tion, based on our observation that these HOT regions are asso-
ciated with highly responsive target genes when exposed to
hormones such as estrogen. It will be important to functionally
characterize these selected regions, and we have begun to
test a representative sample of these HOT regions (>500) in
reporter gene assays.
Further, it is conceivable that germline variation or somatic
mutations in such regions may have a major impact on gene
expression of breast cancer-related genes, thereby playing
an important role in breast carcinogenesis. With the growing
number of sequenced breast cancer genomes, we expect that
ourmap of the critical cis-regulatory elements will be an essential
resource to identify noncoding driver mutations or suscepti-
bility SNPs in breast cancer. This idea also warrants further
testing, and with large-scale sequencing projects such as the
Cancer Genome Atlas underway for breast cancer (http://
cancergenome.nih.gov/cancersselected/breastductal), the re-
gulatory map presented here can act as a guide for identifying
candidate functionally relevant variants.
Another key finding from this study is that specific NRs, as well
as their associated TFs, appear to have a preference to be re-
cruited to specific categories of regulatory elements. Histori-
cally, the study of gene regulation by NRs had been restricted
by the focus on binding to promoters or promoter-proximal
gene regions. Recent studies suggested that the majority of
binding sites for NRs such as ERa, AR, PPARg, RARs, GR, and
VDR occur distally to TSSs. While our study confirms these find-
ings for many factors, we also found a subset of NRs such as
TR2, COUP-TF1, and NURR1 that appear to be recruited at
higher frequency to promoter-proximal binding regions. Interest-
ingly, the preferential recruitment of these two sets of factors to
different binding regions correlates with H3K4me3 levels and is
independent of the proximity of these regions to annotated
TSSs. These findings define the existence of two distinct NR
groups. One group appears to preferentially associate with
more distal enhancers while the other associates with promoters
or proximal enhancers. In the future, it will be important to deter-
mine whether and how the chromatin status affects the recruit-
ment of these factors or whether the presence of these factors
affects the chromatin structure.
Finally, the identification of factors with shared binding regions
in our data set enables predictions about functional interactions
of NRs and other TFs that may be the basis for novel therapeutic
strategies in breast cancer. We demonstrate here a functional
antagonistic interaction between RARs and PPARd inferred
from the similarity of their genomic binding patterns, suggesting
that the combination of RAR activation and PPARd inhibition548 Cell Reports 3, 538–551, February 21, 2013 ª2013 The Authorsmay synergistically inhibit breast cancer growth. We expect
that the interplay of other druggable NRs will be uncovered
from the analysis of their genomic target sites for which this
study provides a comprehensive framework.
EXPERIMENTAL PROCEDURES
Generation of BAC Transgenic MCF-7 Cell Lines
The BACs (Table S10) were obtained from Invitrogen. A localization and affinity
purification cassette was inserted as a C-terminal fusion using ET cloning, and
BAC DNA was extracted and transfected into MCF-7 breast cancer cells
(ATCC HTB-22) for the generation of stable BAC transgenic cell lines as previ-
ously described (Poser et al., 2008).
ChIP-chip and FAIRE-chip
Cells at 80% confluency (5 3 106 cells per FAIRE or ChIP) cultured in 10%
fetal bovine serum (FBS) Dulbecco’s modified Eagle’s medium (DMEM) (for
orphan NRs and non-NR TFs) or 10% charcoal-stripped FBS DMEM in
the presence of a specific NR agonist (Table S10) were subjected to FAIRE
(Giresi et al., 2007) or ChIP as previously described (Hua et al., 2009) with
the following antibodies: goat anti-GFP (raised against His-tagged full-
length EGFP and affinity-purified with GST-tagged full-length EGFP), anti-
H3K4me1 (ab8895) from Abcam, anti-H3K4me3 (ab8580) from Abcam,
anti-H2AZ-ace (ab18262) from Abcam, anti-H3R17me2 (ab8284) fromAbcam,
anti-H3K27me3 (17-622) from Upstate.
ChIPed DNA, DNA from FAIRE, and input DNA were subjected to linker-
mediated PCR amplification and fragmentation and were end-labeled with
biotin using the GeneChip WT Double-Stranded DNA Terminal Labeling Kit
(Affymetrix) as previously described. The resulting labeled samples were
hybridized to Affymetrix GeneChip Human Tiling 2.0R Array Set following the
Affymetrix Chromatin Immunoprecipitation Assay Protocol. Independent bio-
logical triplicates were performed for each TF, histone mark, or FAIRE as
well as the control (input DNA).
Microarray Gene Expression Profiling
MCF-7 cells cultured for 48 hr in medium with 10% charcoal-stripped FBS
were treated with the following NR ligands: estradiol/E2 (ERa agonist),
AM580 (RARA agonist), CD437 (RARG agonist), GW0742 (PPARD agonist),
R5020 (PGR agonist), and dexamethasone (GR/NR3C1 agonist). Total RNA
samples were labeled by direct incorporation of cyanine 3-labeled CTP using
the Agilent Low RNA Input Linear Amplification Kit PLUS (One-Color) (Agilent
Technologies) and hybridized to Agilent Human Genome Oligo Microarrays
(4 3 44K) (Agilent Technologies). Hybridized microarrays were scanned using
a GenePix 4000B scanner (Molecular Devices) at 5 mm resolution. All experi-
ments were performed in triplicate.
ChIP-chip Data Analysis
ChIP-chip tiling array data were normalized and analyzed with Affymetrix Tiling
Analysis Software (TAS) as previously described (Hua et al., 2009) using a
p value cut-off of 1e-3. The preliminary binding regions were then subjected
to four steps of filtering to remove false-positive binding regions. The genomic
coordinates of the identified binding regions for each TF and genes with a TSS
within 50 kb to a specific binding region are provided in Tables S11 and S12,
respectively.
Conservation Analysis for TF Binding Regions
TF binding regions were aligned at their centers and were extended 3 kb to
each side. Base-by-base phastCons conservation scores (Siepel et al.,
2005) based on the multiple alignment of five vertebrate species (human, rat,
mouse, chicken, and Fugu) were retrieved (http://compgen.bscb.cornell.
edu/acs/conservation/), and the mean of phastCons scores at each position
was calculated and plotted in a heatmap.
Identification of HOT Regions
HOT regions were identified by Gaussian kernel density estimation across the
genome with a bandwidth of 300 bp, using the centers of TF binding regions.
The complexity of the HOT region was defined as the sum of TFs that contrib-
uted at least 0.1 to its strength in kernel density. The boundaries of each HOT
region peak were derived as the maximum distance from the HOT region to
any contributing TF extended by 150 bp. Binding regions with TF binding
complexity larger than 8 were defined as HOT regions.
Analysis of Chromatin Signal Intensity Data and HOT Region
Enrichment
ChIP-chip and FAIRE-chip data for chromatin activity marks were processed
using the same TAS parameters as used for the TF ChIP-chip data. The
PolII data were obtained from a previous study in MCF-7 cell line
(Carroll et al., 2006). Processed signal intensity data in HOT regions were
plotted for FAIRE, H2AZace, H3K27me3, H3K4me1, H3K4me3, H3R17me2,
and PolII.
Analysis of Microarray Gene Expression Data
Agilent Feature Extraction software (version 9.5.3, Agilent Technologies) was
used for feature extraction. LIMMA (Smyth, 2004) was used for preprocessing,
log transformation, and quantile normalization, and to identify differentially ex-
pressed genes between ligand treatment and control experiments. A cutoff of
0.05 for Benjamini-Hochberg corrected p values was used to call significant
changes of transcript levels.
Analysis of the NR Regulatory Network and Network Motif
Enrichment
Each network node represents a TF. For two nodes (e.g., A and B), there are
three types of edges. Type I, A binds within 50 kb to the TSS of B. Type II, after
treatment with A’s ligand, the expression of A’s target genes are significantly
affected by the binding of B within 50 kb to the TSSs of these genes. Type
III, after treatment with A’s ligand, the expression of B changes significantly
after 24 hr. The network was imported into Cytoscape v. 2.8.1(Smoot et al.,
2011), and organized using unweighted force-directed layout.
Network motif enrichment analysis was performed by first collapsing the
type II and type III edges into one category. Then we generated 1,000 random
networks with the same degree distribution and number of edges. If the
number of motif occurrences in the original network was larger than in 95%
of the random networks, we called themotif as a significantly enriched network
motif.
Analysis of Functional Module Enrichment in HOT Region Target
Genes
The target gene set of all HOT regions was tested against all 5,607 gene sets
obtained from MSigDB Release 3.0 (Subramanian et al., 2005) for enrichment
analyses using one-tail hypergeometric test. In addition, the BC1000 set (Witt
et al., 2006), a manually curated breast cancer-related gene set was also
included in this analysis. A cutoff of 0.05 for Bonferroni corrected p values
was used. Also, gene sets with less than 150 genes were removed from the
analysis.
MDS Analysis of Pairwise TF Binding
We determined pair-wise TF binding distances with the following distance
metric between the binding regions of two factors: distance = overlap (A and
B) / min (A, B). The MDS plot was generated from all pairwise distances with
the cmdscale function in R.
Analysis of Target Gene Enrichment in Breast Cancer Expression
Profiles
PPARd/RAR common target genes were identified as genes with at least
a single individual or shared binding site for PPARd and RARs within 50 kb
to the TSS. Gene expression data for breast cancer subtypes were obtained
from publically available data (Hu et al., 2006). Clustering of genes and
breast cancer samples was performed with Cluster 3.0 (http://bonsai.hgc.jp/
mdehoon/software/cluster/software.htm). Centroid linkage clustering was
performed with both genes and samples. The frequency of PPARd and RAR
binding within 50 kb to the genes’ TSSs was calculated for a sliding window
of 50 neighboring genes.CAnalysis of TF Expression as Clinical Outcome Predictors
Previously published gene expression and clinical outcome data (Chang et al.,
2005) was used. Two-point optimal cut point analysis was performed using the
X-Tile package (Camp et al., 2004) to group patient sample data into three
categories based on TF expression levels (low, medium, high). Kaplan-Meier
survival curves for patient overall survival were plotted and the Log-Rank
test was performed with the R ‘‘survival’’ package.
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ChIP-chip data reported in this study have been deposited in the NCBI Gene
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